For the third quarter of the fiscal year ending March 2026, net sales were \u00a520,611 million (6.8% increase YoY), operating income was \u00a52,478 million (5.5% increase YoY), and net income attributable to owners of parent for the quarter was \u00a52,039 million (9.1% increase YoY).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4094","jir_company_name":"Nippon Chemical Industrial Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4094-20260209-02.pdf","jir_short_summary":"For the third quarter of the fiscal year ending March 2026, net sales were \u00a520,611 million (6.8% increase YoY), operating income was \u00a52,478 million (5.5% increase YoY), and net income attributable to owners of parent for the quarter was \u00a52,039 million (9.1% increase YoY).","jir_summary":"### Performance Overview\nDuring the cumulative third quarter period of the fiscal year ending March 2026 (April 1, 2025 to December 31, 2025), net sales amounted to \u00a520,611 million (6.8% increase YoY), operating income was \u00a52,478 million (5.5% increase YoY), ordinary income was \u00a52,859 million (8.6% increase YoY), and net income attributable to owners of parent for the quarter was \u00a52,039 million (9.1% increase YoY). The increase in net sales reflects growth in both the pharmaceutical and building materials businesses, with the pharmaceutical business benefitting particularly from a recovery in shipments in the electronics industry and improved performance of overseas subsidiaries. Meanwhile, the equity ratio declined from 85.6% at the end of the same period last year to 84.0%.\n\n### Segment Performance and Dividend Status\nThe pharmaceutical business recorded net sales of \u00a517,680 million (7.3% increase YoY) and segment profit of \u00a52,787 million (8.8% increase YoY). The building materials business posted net sales of \u00a52,931 million (4.2% increase YoY) and segment profit of \u00a5446 million (5.3% decrease YoY), impacted by a decline in new housing starts and a challenging business environment. Regarding dividends, the annual dividend forecast for fiscal 2026 is \u00a590 (up from \u00a575 last year), with a payment of \u00a545 planned at the end of the second quarter.","jir_financial_highlights":"Net Sales: \u00a520,611 million (6.8% increase YoY)\nOperating Income: \u00a52,478 million (5.5% increase YoY)\nOrdinary Income: \u00a52,859 million (8.6% increase YoY)\nNet Income Attributable to Owners of Parent (Quarterly): \u00a52,039 million (9.1% increase YoY)\nEquity Ratio: 84.0% (Decrease YoY (85.6% \u2192 84.0%))\nNumber of Issued Shares (Common Stock): 20,280,000 shares (Unknown)\nNumber of Treasury Shares: 819,265 shares (Unknown)\nQuarterly Net Income per Share: \u00a5104.78 (Increase YoY (\u00a596.06 \u2192 \u00a5104.78))\nAnnual Dividend (Forecast): \u00a590.00 (Increase YoY (\u00a575.00 \u2192 \u00a590.00))","jir_category":"","jir_hashtags":"#NipponChemicalIndustrial, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: \u00a520,611 million (6.8% increase YoY)\nOperating Income: \u00a52,478 million (5.5% increase YoY)\nNet Income Attributable to Owners of Parent (Quarterly): \u00a52,039 million (9.1% increase YoY)","jir_meta_title":"Nippon Chemical Industrial Third Quarter FY2026 Financial Results: Net Sales \u00a520,611 Million, Up 6.8%","jir_meta_description":"Nippon Chemical Industrial Co., Ltd. releases third quarter financial summary for fiscal year ending March 2026. Net sales \u00a520,611 million (up 6.8% YoY), operating income \u00a52,478 million (up 5.5% YoY), net income \u00a52,039 million (up 9.1% YoY). Dividend forecast raised to \u00a590.","jir_og_title":"Nippon Chemical Industrial Announces Q3 FY2026 Financial Results: Net Sales Up 6.8%","jir_og_description":"Third quarter financial summary for fiscal year ending March 2026: Net sales \u00a520,611 million, operating income \u00a52,478 million, net income \u00a52,039 million. Dividend forecast \u00a590.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[19291,20611],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[2349,2478],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent (Quarterly) Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income (Quarterly)\\\",\\\"data\\\":[1868,2039],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Net Sales (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Business\\\",\\\"Building Materials Business\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Q3 FY2025\\\",\\\"data\\\":[16479,2812],\\\"backgroundColor\\\":\\\"#76b7b2\\\"},{\\\"label\\\":\\\"Q3 FY2026\\\",\\\"data\\\":[17680,2931],\\\"backgroundColor\\\":\\\"#59a14f\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_profit_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Profit (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Business\\\",\\\"Building Materials Business\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Q3 FY2025\\\",\\\"data\\\":[2560,471],\\\"backgroundColor\\\":\\\"#edc949\\\"},{\\\"label\\\":\\\"Q3 FY2026\\\",\\\"data\\\":[2787,446],\\\"backgroundColor\\\":\\\"#af7aa1\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":17390,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-25763","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n